In the realm of public health, where every life saved is a triumph, the unexpected alliance between doctors and autonomous vehicles (AVs) is a fascinating development. The recent open letter from doctors Jonathan Slotkin and Eric Topol, both renowned figures in the medical community, advocates for the widespread adoption of AVs as a public health imperative. This move adds a critical public health perspective to the ongoing debate surrounding AV policy, which has been primarily driven by the industry itself. The doctors' stance is particularly intriguing given the potential implications for road safety and the broader healthcare landscape.
The Doctors' Perspective
Slotkin and Topol, both champions of AI-enabled health tech, have taken a bold step by organizing this open letter. Their primary argument is that AVs are already making a tangible difference in road safety, and this should be a compelling reason for policymakers to take action. The letter highlights a 2025 peer-reviewed study by Waymo, the AV industry leader, which examined an impressive 56.7 million fully driverless miles on public roads. The findings were remarkable: an 85% reduction in serious-injury-or-worse crashes compared to human drivers.
What makes this study and the doctors' advocacy particularly interesting is the potential for AVs to complement, rather than replace, existing safety measures. Slotkin, a neurosurgeon, emphasizes the personal connection to this issue, stating, 'I'm a neurosurgeon that practices and frequently has blood on my hands from car crashes, including those involving children.' This sentiment resonates with many in the medical community, who see the potential for AVs to reduce the devastating impact of road accidents.
However, the doctors' call for action goes beyond the immediate safety benefits. They urge state and federal authorities to 'responsibly act on the growing safety evidence' around AVs, suggesting that the technology is ready for wider deployment. This is a significant shift in the narrative, as it challenges the notion that AVs are still in their experimental phase.
The Data Dilemma
The doctors' letter also brings to light a critical issue: the lack of standardized data reporting by AV companies. The study cited by Slotkin and Topol was conducted by Waymo employees, and this raises questions about the objectivity and transparency of the data. The doctors argue that standardized, enhanced federal data-reporting requirements are essential to enable safety comparisons and build public trust in AV technology.
This is a crucial point, as the medical community relies on robust, transparent data to make evidence-based decisions. The current situation, where only a few AV companies publish such data, creates an imbalanced playing field. Slotkin's criticism of the situation is valid, as it highlights the need for a level playing field where all AV companies can be held accountable for their safety records.
The Broader Implications
The doctors' advocacy for AVs as a public health issue has broader implications. It raises a deeper question about the role of technology in addressing societal challenges. In this case, AVs have the potential to significantly reduce road accidents, which are a leading cause of injury and death worldwide. This could free up healthcare resources and reduce the burden on emergency services.
However, the doctors' stance also invites a broader discussion about the ethical and societal implications of AVs. For instance, what happens when AVs are involved in accidents? How do we ensure that the benefits of AVs are equitably distributed, and what are the potential unintended consequences of widespread adoption? These are complex questions that require careful consideration.
The Way Forward
The doctors' open letter is a call to action for policymakers and the AV industry. It urges a shift towards evidence-based frameworks that encourage the deployment of AVs where the data supports it. This is a pragmatic approach, as it acknowledges the potential of AVs while also recognizing the need for careful regulation. The letter specifically cites efforts in New York, Massachusetts, Washington, Minnesota, and Washington, D.C., to block robotaxis, as examples of unwarranted regulatory barriers that need to be addressed.
In my opinion, the doctors' advocacy is a welcome development in the AV policy debate. It brings a much-needed public health perspective to the discussion, which has been dominated by industry and regulatory concerns. The doctors' personal connection to the issue adds a layer of authenticity to their argument, making it harder for policymakers to ignore the potential benefits of AVs. However, the challenge now lies in translating this advocacy into concrete policy changes that balance safety, innovation, and public trust.
As the AV industry continues to evolve, the role of public health advocates like Slotkin and Topol will be crucial in shaping the future of this technology. Their open letter is a powerful reminder that the benefits of AVs extend beyond the roads, and that the medical community has a vital role to play in this transformative journey.
